.png "Theravance Biopharma (NASDAQ: TBPH)")
Today, the SVP & CFO of Theravance Biopharma (NASDAQ: TBPH), Renee Gala, sold shares of TBPH for $758.9K.
Following Renee Gala’s last TBPH Sell transaction on August 17, 2015, the stock climbed by 10.9%.
See today’s analyst top recommended stocks >>
Based on Theravance Biopharma’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $8.32 million and GAAP net loss of $65.09 million. In comparison, last year the company earned revenue of $3.09 million and had a GAAP net loss of $65.32 million. Currently, Theravance Biopharma has an average volume of 174.7K. The Company has a Price to Book ratio of 19.8686.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $42.75, reflecting a -46.2% downside.
Renee Gala’s trades have generated a 73.6% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Theravance Biopharma, Inc. operates as a biopharmaceutical company, which focuses on the discovery, development and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.
